MyFinsight
Home
Blog
About
Contact
Proceeds from issuance on
common stock and...
$161,763K
Proceeds from exercise of
options
$1,582K
Proceeds from maturities
and sales of...
$101,000K
Net cash provided by
financing activities
$163,345K
Net cash provided by
investing activities
$100,940K
Canceled cashflow
$60K
Net
(decrease)/increase in cash and cash...
$226,777K
Canceled cashflow
$37,508K
Purchase of property and
equipment
$60K
Accounts payable and
accrued...
$11,725K
Stock-based compensation
$5,858K
Prepaid expenses and
other assets
-$2,089K
Net amortization of
premiums and discounts on...
-$338K
Non-cash lease expense
$273K
Depreciation
$44K
Net cash used in
operating activities
-$37,508K
Canceled cashflow
$20,327K
Net loss
-$56,211K
Accounts payable and
accrued...
-$1,354K
Operating lease
liabilities
-$270K
Back
Back
Cash Flow
Bicara Therapeutics Inc. (BCAX)
Bicara Therapeutics Inc. (BCAX)
source: myfinsight.com